Phathom Pharmaceuticals, Inc. (PHAT) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-02-26
How it makes money
It earns revenue from patients and insurers buying VOQUEZNA, with growth driven by rising prescription volumes and expanding prescriber adoption for GERD.
It sells acid-blocking medication for gastrointestinal conditions. Profitability depends on the volume of prescriptions written by doctors and the company's ability to secure broad coverage from health insurance payers.
What protects it: the moat
It relies on regulatory exclusivity and patent rights to prevent competitors from launching identical treatments until 2032.
Management asserts that these government-granted protections provide a barrier to entry. Without these, competitors could potentially market generic or similar versions of the drug.
What growth costs
It reinvests heavily in a targeted sales force, clinical trials for new indications, and general corporate operations to support commercial expansion.
The filing does not provide specific capital expenditure figures. It notes that growth relies on ongoing efforts to engage healthcare providers and potential future acquisitions of other product candidates.
What could damage it
Loss of health insurance coverage or reimbursement would directly collapse its ability to generate the revenue needed to sustain operations.
Because patients depend on insurance to afford these specialized drugs, the company's entire business model is vulnerable to any reduction in coverage or pricing policies by private and governmental health insurers.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.